What Happened?

A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs. 

This potential move would target pharmaceutical companies that have not negotiated deals to lower drug prices in the United States. The news sparked a significant sell-off in the sector, with the Nifty Pharma index declining over 5% as all its constituent stocks traded lower. The concerns were particularly pronounced for international drugmakers who rely on the US market.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Medical Devices & Supplies - Imaging, Diagnostics company GE HealthCare (NASDAQ: GEHC) fell 2.7%. Is now the time to buy GE HealthCare? Access our full analysis report here, it’s free.
• Branded Pharmaceuticals company Collegium Pharmaceutical (NASDAQ: COLL) fell 3%. Is now the time to buy Collegium Pharmaceutical? Access our full analysis report here, it’s free.

Zooming In On Collegium Pharmaceutical (COLL)

Collegium Pharmaceutical’s shares are somewhat volatile and have had 13 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 17 days ago when the stock gained 2.9% on the news that easing crude oil prices helped lift investor sentiment and reduce inflation worries. 

The retreat in oil prices provided temporary relief to a market that was volatile amid geopolitical tensions. Lower energy costs can help temper inflation, which had been a primary concern for the economy and corporate profits. 

As a result, major indices like the S&P 500 and Dow Jones Industrial Average saw significant gains. This positive macroeconomic development boosted investor confidence across most sectors, leading to widespread buying activity that included major stocks within the healthcare industry, which rose in tandem with the overall market.

Collegium Pharmaceutical is down 28.9% since the beginning of the year, and at $32.35 per share, it is trading 35.1% below its 52-week high of $49.84 from December 2025. Despite the year-to-date decline, investors who bought $1,000 worth of Collegium Pharmaceutical’s shares 5 years ago would now be looking at an investment worth $1,377.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.